Background and objectives: Oral mucositis is one of the main adverse events of cancer
treatment with chemotherapy or radiation therapy. It presents as erythema, atrophy or/and …

Purpose To update the clinical practice guidelines for the use of growth factors and
cytokines for the prevention and/or treatment of oral mucositis (OM). Methods A systematic …

PURPOSE To provide evidence-based recommendations for prevention and management
of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies …

Bone regeneration following surgery, trauma, or any other condition is an autologous
process that can fail, necessitating the requirement of novel procedures and materials …

Background Oral mucositis is a side effect of chemotherapy, head and neck radiotherapy,
and targeted therapy, affecting over 75% of high‐risk patients. Ulceration can lead to severe …

Context: Oral mucositis is one of the most common side effects of cancer treatments, which
affects all the patients receiving radiation treatment. Oral and oropharyngeal mucosa are …

Introduction: Oral mucositis is a significant unmet clinical need for many cancer patients. The
biological complexity of mucositis' pathogenesis provides a number of mechanistic targets …

Purpose This systematic review aimed to assess the updated literature for the prevention of
salivary gland hypofunction and xerostomia induced by non-surgical cancer therapies …

RESULTS Seven sources of information were consulted, resulting in 75,986 publications
that included the descriptors; of these, only 133 articles were directly related to the subject …

Objective To test whether or not topically administered recombinant human epidermal
growth factor (rh EGF) accelerates the early healing phase of oral soft tissue wounds …